Abbott Laboratories (ABT)
Data as of Nov 2, 4:02 PM ETPrices may be delayedHow our data works
Res / Sup are automatic swing levels for educational reference only — not signals or advice.
Prices may be delayed. For informational purposes only — not investment advice.
ABT key stats
ABT GlowScore: Active
A 0–100 read on today's activity from volume, momentum and intraday range. Not a buy or sell signal.
About Abbott Laboratories
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
What's moving ABT today
Updated November 3, 2026As of November 3, 2026, Abbott Laboratories (ABT) stock climbed to $110.16, up 3.73% (+$3.96) versus the previous close. On the day, shares have traded between $106.40 and $110.48. That puts ABT around the middle of its 52-week range of $81.97 to $132.03. Abbott Laboratories operates in the pharmaceutical preparations space and carries a market capitalization of roughly $190.62 billion, with about 8.85 million shares changing hands.
Latest ABT news
- Spinal cord stimulator lawsuits surge: what is going wrong?medicaldevice-network.com· Nov 3, 7:52 AM ET
- Why Did Boston Scientific Stock Jump?trefis.com· Nov 3, 7:41 AM ET
- BridgeBio to Present New Acoramidis Data on Heart Failure Events in ATTR-CM at the American Heart Association Scientific Sessions 2026Yahoo Finance· Nov 3, 7:30 AM ET
- Abbott’s Amulet 360 demonstrates strong one-year outcomes in AFib patientsclinicaltrialsarena.com· Nov 3, 7:25 AM ETLAA
- What Are Danaher Investors Betting On?trefis.com· Nov 3, 6:56 AM ET
- Should Retail Leadership Reset Require Action From Marzetti (MZTI) Investors?Yahoo Finance· Nov 2, 7:17 PM ETMZTI
- 39 New Companies Join the 2026 Fortune Best Companies to Work For Southeast Asia ListYahoo Finance· Nov 2, 7:00 PM ET
- Abbott Touts Favorable Outcomes In Cardiovascular Device TrialsYahoo Finance· Nov 2, 12:48 PM ETLAA
Source: Yahoo Finance RSS · Updated November 3, 2026
Want ABT headlines, alerts and AI research in one place? Create a free account →
ABT buzz on Stocktwits
18,160 watchersadded $ABT Nov 11/117 call spreads
@harmongreg· Nov 2, 3:45 PM ET
$ABT great run for us - we remain on track for $120+ in the coming weeks 🥂
@DBRGLong· Nov 2, 3:38 PM ET· Bullish
$ABT: it's moving day. We in calls in the Live Options Room from last week. Safe haven play.
@Dr_Stoxx· Nov 2, 10:03 AM ET
$ABT Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System "SonicForce is an investigational coronary intravascular lithotripsy (IVL) system that u…
@AlertsAndNews· Nov 1, 5:56 PM ET
$ABT 🏥 Abbott Laboratories reported strong 30-day outcomes and high procedural success from the TECTONIC clinical trial of its investigational SonicForce Coronary Intravascular Lithotripsy System for treating coronary calcium. Selected from hundreds of headlines
@Rayvio_News_Filter· Nov 1, 3:45 PM ET
Source: Stocktwits. User posts are opinions, not verified facts. See what's trending →
ABT Congress & insider trades
Congress amounts are the disclosed ranges; filings can lag the trade date by up to 45 days.
AI research on ABT
Get an instant AI breakdown of the bull & bear case, key risks, and what analysts are watching.
Not financial advice. This page is for educational purposes only. Data comes from third-party sources, may be delayed or incomplete, and should not be the basis of any investment decision.